Amyloid-Beta Associated with Chitosan Nano-Carrier has Favorable Immunogenicity and Permeates the BBB
Authors:
- 16 July 2009
- journal article
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 10 (3) , 900-905
Abstract
Subfragments of amyloid-beta (Aβ) appear to protect neurons from Alzheimer’s disease (AD). The permeability of the blood–brain barrier (BBB) has limited in vivo research. The aim of this study is to explore permeation of the BBB by chitosan nanoparticles loaded with Aβ and to evaluate immunogenicity of these particles. Chitosan microspheres were prepared by mechanical stirring emulsification methods combined with chemical crosslinking. Morphological characteristics of the nanoparticles were examined using high-resolution transmission electron microscopy. The peptide association efficiency was determined by high-performance liquid chromatography. Fluorescently labeled chitosan nanoparticle-intramembranous fragments of Aβ (NP-IF-A) were administered systemically to mice in order to evaluate brain translocation by fluorescence microscopy. The immunogenicity of the nano-vaccine was determined by enzyme-linked immunosorbent assay (ELISA). All nanoparticles analyzed were well-separated, roughly spherical structures with uniform particle size distribution in the range of 15.23 ± 10.97 nm. The peptide association efficiency was 78.4%. The brain uptake efficiency of nano-antigen was 80.6%; uptake efficiency of antigen alone was only 20.6%. ELISA showed that the nano-vaccine had favorable immunogenicity. A chitosan nano-carrier for Aβ allowed permeation of the BBB and was non-immunogenic. These findings indicate that this novel targeted nano-vaccine delivery system can be used as a carrier for Aβ. This system will further research of peptide vaccines for AD.Keywords
This publication has 24 references indexed in Scilit:
- C-terminal peptides coassemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicityProceedings of the National Academy of Sciences, 2008
- Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymersInternational Journal of Pharmaceutics, 2007
- Development and Brain Delivery of Chitosan−PEG Nanoparticles Functionalized with the Monoclonal Antibody OX26Bioconjugate Chemistry, 2005
- The blood–brain barrier: an overviewNeurobiology of Disease, 2004
- Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid β peptide and interleukin-1βNeuroscience Letters, 2002
- Crosslinked chitosan microspheres for encapsulation of diclofenac sodium: effect of crosslinking agentJournal of Microencapsulation, 2002
- Microencapsulation of Chlorpheniramine Maleate–Resin Particles with Crosslinked Chitosan for Sustained ReleasePharmaceutical Development and Technology, 1999
- Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan–EDTA conjugatesJournal of Controlled Release, 1998
- Physiological production of the β-amyloid protein and the mechanism of Alzheimer's diseaseTrends in Neurosciences, 1993
- Serum autoantibodies in patients with Alzheimer's disease and vascular dementia and in nondemented control subjects.Stroke, 1992